Afficher la couverture 'TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma | Guillerey, Camille' en grand format
/5

0 avis

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Archive ouverte

Guillerey, Camille | Harjunpää, Heidi | Carrié, Nadège | Kassem, Sahar | Teo, Tricia | Miles, Kim | Krumeich, Sophie | Weulersse, Marianne | Cuisinier, Marine | Stannard, Kimberley | Yu, Yuan | Minnie, Simone | Hill, Geoffrey | Dougall, William | Avet-Loiseau, Hervé | Teng, Michele | Nakamura, Kyohei | Martinet, Ludovic | Smyth, Mark

Edité par CCSD ; American Society of Hematology -

International audience. Key Points TIGIT expression is upregulated on CD8+ T cells during MM progression and is associated with impaired effector functions. TIGIT deficiency or blockade protects mice against MM and improves effector functions of myeloma patient CD8+ T cells.

Consulter en ligne

Suggestions

Du même auteur

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model

Archive ouverte | Guillerey, Camille | CCSD

International audience

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

Archive ouverte | Weulersse, Marianne | CCSD

International audience

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

Archive ouverte | Weulersse, Marianne | CCSD

International audience. CD8+ T cells within the tumor microenvironment (TME) are exposed to various signals that ultimately determine functional outcomes. Here, we examined the role of the co-activating receptor CD2...

Chargement des enrichissements...